Hong Kong Stock Announcement Gold Mining | CHINA MOBILE's profit attributable to shareholders for 2024 is 138.4 billion yuan, a year-on-year increase of 5%, with digital transformation revenue reaching 278.8 billion yuan.

Geely Autos (00175) announced its annual performance, with a profit attributable to Shareholders of 16.632 billion yuan, a year-on-year growth of 213%, and export sales hitting a historical high; AAC TECH (02018) published its annual performance as well, with a profit attributable to Shareholders of 1.797 billion yuan, reflecting a year-on-year growth of 142.7%, and a comprehensive breakthrough in its core Business.

Zhitong FinanceMar 20 22:52

Sino Biopharmaceutical's 2024 Attributable Profit Jumps 50%

MT NewswiresMar 20 20:28

SINO BIOPHARM (01177) will distribute a final dividend of 4 Hong Kong cents per share on July 10.

SINO BIOPHARM (01177) announced that it will distribute a final dividend of 4 Hong Kong cents per share on July 10, 2025.

Zhitong FinanceMar 20 16:51

SINO BIOPHARM (01177.HK) expects a profit growth of approximately 50.1% for the fiscal year 2024, with revenue from innovative products reaching 12.06 billion yuan.

On March 20, Gelonghui reported that SINO BIOPHARM (01177.HK) announced that for the year ending December 31, 2024, the group recorded revenues of approximately 28,866.16 million yuan, an increase of about 10.2% compared to the same period last year. Gross profit was approximately 23,529.94 million yuan, an increase of about 10.9% compared to the same period last year. The gross profit from the Traditional Chinese Medicine modern formulation and Western Medicine Business segments was approximately 23,450 million yuan, an increase of about 11.0% compared to the same period last year. The gross profit from Other Business segments totaled approximately 79.94 million yuan, a decrease of about 5.6% compared to the same period last year.

Gelonghui FinanceMar 20 16:38

How strong are the Hong Kong pharmaceutical stocks right now? The Innovative Drugs Index has risen over 30% this year, reaching a near 16-month high.

① The Innovative Drugs Index in the Hong Kong stock market has increased by over 30% this year; why can it compete with Technology stocks? ② There has been a "small peak" in the commercialization of individual stocks; how do Institutions perceive the future market direction?

cls.cnMar 20 16:36

In the "Blue Chip", SINO BIOPHARM (01177.HK) achieved a net profit of 3.5 billion RMB for the entire year, an increase of 50.1%, and declared a final dividend of 4 Hong Kong cents.

SINO BIOPHARM (01177.HK) announced its annual results for the year ending December last year, with a revenue of 28.866 billion yuan (RMB), an increase of 10.2% year-on-year. The net profit was 3.5 billion yuan, a 50.1% increase year-on-year; earnings per share were 19.13 cents. A final dividend of 4 Hong Kong cents was declared, compared to 3 Hong Kong cents in the same period last year. Together with the interim dividend of 3 Hong Kong cents already distributed, the total dividend for the year amounted to 7 Hong Kong cents. Non-Hong Kong Financial Reporting Standards adjusted net profit increased by 33.5% year-on-year to approximately 3.46 billion yuan. Adjusted earnings per share were 18.9 cents. During the period, the gross margin increased by 0.5 percentage points year-on-year to 81.5%;

AASTOCKSMar 20 16:33

SINO BIOPHARM: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2024

HKEXMar 20 16:30 · Announcements

Is the CRO Concept "Return of the King"? WuXi AppTec aggressively attacks, leading stocks celebrate after performance!

Release the signal?!

Gelonghui FinanceMar 18 13:42

GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.

GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.

Zhitong FinanceMar 17 09:18

Is the breakthrough path all in AI? Chain pharmacies are facing a wave of closures and an era of low profits.

① In 2024, particularly in the second half of the year, chain pharmacies will face a large-scale wave of closures, and leading chain pharmacies will generally enter a low-profit era. ② AI is also being assigned higher expectations in helping pharmacies reduce costs and increase efficiency. ③ Publicly available large models, due to a lack of support from vertical domain data, are still insufficient to support the actual Business Operation of pharmacies.

cls.cnMar 16 14:09

AI and policy drive together! Hong Kong stocks in the pharmaceutical sector make a collective comeback, with WUXI BIO surging over 13% leading the Industry.

① What technological breakthroughs have driven the improvement of research and development efficiency in the Biomedical Industry? ② What are the reasons for the leading increase in WuXi's affiliated companies?

cls.cnMar 14 13:19

Hong Kong stocks are experiencing fluctuations | CRO Concept stocks are warming up. The integration of AI and CXO has entered a new stage. Institutions claim that the external environment for CRO may be improving.

As of the time of writing, the CRO Concept has warmed up, with VIVA BIOTECH (01873) rising by 11.89% to 1.6 HKD; WUXI BIO (02269) increasing by 10.3% to 25.7 HKD; PHARMARON (03759) up by 5.67% to 16.04 HKD; and TIGERMED (03347) climbing by 5.86% to 37.05 HKD.

Zhitong FinanceMar 14 10:47

Goldman Sachs: The Medical Care Industry in China is expected to return to normal this year without a V-shaped rebound.

Goldman Sachs published a Research Report stating that 2025 will be a year when China's Medical Care Industry moves closer to normalization. Pharmaceutical companies are expected to gradually adapt to the new normal, but it is anticipated that the Industry will not be able to quickly recover and achieve a V-shaped rebound from the impacts of recent policies such as anti-corruption measures and the national medical security diagnosis-related grouping reform. Additionally, Goldman Sachs believes that while generative AI has become a hot topic in the pharmaceutical industry, the application of AI is still premature and is not expected to have a significant impact on the Industry in the short term. The firm predicts that more disruptive Technology applications will emerge in the future, reshaping the research and development processes and the ROI of the pharmaceutical industry based on recent industry developments.

AASTOCKSMar 13 15:52

Goldman Sachs' investment ratings and Target Price for China's Medical health stocks (table)

Goldman Sachs released a research report, detailing the latest investment ratings and target prices for Chinese Medical health stocks as follows: Stock | Investment Rating | Target Price (HKD) HANSOH PHARMA (03692.HK) | Buy | 20.97 -> 21.51 SINO BIOPHARM (01177.HK) | Buy | 4.1 -> 3.96 CSPC PHARMA (01093.HK) | Buy | 8.52 FOSUN PHARMA (02196.HK) | Neutral | 18.18 -> 16.83 LIVZON PHARMA (0151

AASTOCKSMar 13 15:43

All the way up! The Innovative Drugs Sector in Hong Kong stocks surged collectively, with multiple stocks doubling this year. Who is reshaping the valuation?

The rise in the Hong Kong stock market's Innovative Drugs Sector continues. Market analysts point out that this wave of Innovative Drugs momentum benefits from a combination of factors including market sentiment, policy, and the realization of the companies' own commercial value.

Securities TimesMar 13 09:50

[Brokerage Focus] China International Capital Corporation: There is still significant room for improvement in China's Consumer market.

Gold Sentinel Financial News | The China International Capital Corporation report points out that, from multiple dimensions, the ratio of Consumer spending to GDP in China is relatively low. In international comparisons, the proportion of Commodity consumption to GDP in China does not deviate significantly from its economic development stage, but the deviation of service consumption's share of GDP from its economic development stage is more pronounced. The bank states that looking to the future, there is still significant room for improvement in China's Consumer spending, where the potential for service consumption is greater than that for Commodity consumption, especially in areas like Medical Insurance and cultural entertainment. The potential for Commodity consumption lies more in upgrading, meaning quality enhancement, while the potential for service consumption may primarily focus on increasing quantity. Raising laborers' remuneration will help boost.

King Wu Financial NewsMar 13 09:19

Sino Biopharmaceutical's Drug Study Shows 85.2% Failure-Free Survival Rate for 12 Months

MT NewswiresMar 11 18:45

Hong Kong stock movement | SINO BIOPHARM (01177) rises over 4% as the clinical research results of the self-developed Innovative Drug 'Rovafazitinib' phase IB/IIA are published in 'Blood'.

SINO BIOPHARM (01177) rose more than 4%, currently up 4.48%, priced at 3.5 HKD, with a transaction amount of 0.203 billion HKD.

Zhitong FinanceMar 11 11:11

SINO BIOPHARM (01177.HK) Innovative Drugs Lovatibatin announced clinical research results.

SINO BIOPHARM (01177.HK) announced that the clinical research results of the independently developed National Class 1 Innovative Drug "Rovadicitinib" for the treatment of chronic graft-versus-host disease (cGVHD) have been published in the prestigious international hematology journal Blood (IF: 21.0). Rovadicitinib is the first oral small molecule inhibitor in the world that combines both JAK and ROCK dual inhibition mechanisms, targeting JAK1/2 and ROCK1/2, and has both anti-inflammatory and anti-fibrotic effects. The drug is used in the treatment of

AASTOCKSMar 10 23:16

Hong Kong Stock Announcement Gold Mining | SITC's annual profit attributable to shareholders is 1.028 billion US dollars, representing a year-on-year increase of 93.51%.

SINO BIOPHARM (01177): Global first JAK/ROCK inhibitor "Rovadicitinib" phase IB/IIA clinical research results published in "Blood"; SITC's annual shareholder attributable profit of 1.028 billion USD, a year-on-year increase of 93.51%...

Zhitong FinanceMar 10 23:05